Forbes B A, Hicks K E
Department of Clinical Pathology, State University of New York Health Science Center, Syracuse 13210.
J Clin Microbiol. 1993 Jul;31(7):1688-94. doi: 10.1128/jcm.31.7.1688-1694.1993.
The emergence of epidemic multiple-drug-resistant (MDR) strains of Mycobacterium tuberculosis in conjunction with an increase in the number of reported cases of tuberculosis (TB) represents a major public health problem. In light of a recent outbreak of MDR M. tuberculosis at our center, we began the development of a polymerase chain reaction (PCR) assay for the rapid diagnosis of pulmonary TB using two sets of primers, one based on the IS6110 repeated sequence of M. tuberculosis and the other based on the protein antigen b (PAB). Reaction conditions were first optimized as to the appropriate extraction protocol and the concentrations of primer pairs, nucleotides, and MgCl2. Following a preliminary evaluation of the assay with clinical specimens, extraction and amplification procedures were further modified. PAB and IS6110 primers detected between 2 and 23 and 0.023 and 0.23 CFU of M. tuberculosis, respectively, in pooled, M. tuberculosis-negative sputa by our optimized PCR assay. After routine processing for mycobacteria, 734 specimens were subsequently amplified. DNA for amplification was obtained by boiling and beating the sediments with Tween 20. For each reaction, DNA (10 microliters) was added to an amplification mixture containing 12 pmol of IS6110 primers, 20 pmol of PAB primers, 2 mM MgCl2, 200 microM nucleotides, and 2.5 U of Taq polymerase and the mixture was then amplified for 40 cycles. The sensitivity and specificity of our PCR assay were 87.2 and 97.7%, respectively. We were unable to interpret the results for seven specimens (1%). In our experience, PCR proved to be a useful rapid diagnostic test for TB in a clinical setting and a valuable epidemiological tool for determining exposure groups in the hospital setting. Our findings also underscore the need for the systematic optimization of PCR assay conditions.
结核分枝杆菌多重耐药(MDR)流行菌株的出现,加之报告的结核病(TB)病例数增加,这成为了一个重大的公共卫生问题。鉴于我们中心最近爆发了耐多药结核分枝杆菌疫情,我们开始研发一种聚合酶链反应(PCR)检测方法,用于使用两组引物快速诊断肺结核,一组基于结核分枝杆菌的IS6110重复序列,另一组基于蛋白抗原b(PAB)。首先针对合适的提取方案以及引物对、核苷酸和MgCl2的浓度对反应条件进行了优化。在用临床标本对该检测方法进行初步评估后,对提取和扩增程序进行了进一步修改。通过我们优化的PCR检测方法,PAB和IS6110引物在合并的结核分枝杆菌阴性痰中分别检测到2至23个和0.023至0.23个结核分枝杆菌菌落形成单位(CFU)。在对分枝杆菌进行常规处理后,随后对734份标本进行了扩增。通过将沉淀物与吐温20一起煮沸和振荡来获得用于扩增的DNA。对于每个反应,将10微升DNA加入到含有12皮摩尔IS6110引物、20皮摩尔PAB引物、2毫摩尔MgCl2、200微摩尔核苷酸和2.5单位Taq聚合酶的扩增混合物中,然后将混合物扩增40个循环。我们的PCR检测方法的灵敏度和特异性分别为87.2%和97.7%。我们无法解读7份标本(1%)的结果。根据我们的经验,PCR被证明是临床环境中用于结核病的一种有用的快速诊断测试,也是确定医院环境中暴露人群的一种有价值的流行病学工具。我们的研究结果还强调了对PCR检测条件进行系统优化的必要性。